Tox21BodyMap

Tox21BodyMap maps Tox21 high-throughput screening (HTS) assay targets onto human organs to integrate bioactivity from 9,270 chemicals tested in 971 HTS assays with organ-specific gene expression data for predicting organ-specific chemical effects and generating mechanistic hypotheses.

Key Features:

• Data integration: Integrates bioactivity data from 9,270 chemicals tested in 971 HTS assays from the Tox21 consortium.
• Organ mapping: Maps assay targets to human organs using organ-specific gene expression data.
• Filtering by molecular criteria: Applies gene expression thresholds and activity concentration parameters to refine target-to-organ associations.
• Comprehensive representations: Summarizes chemical bioactivity across Tox21 HTS assay targets using network representations, data tables, and plots.
• Mechanistic interpretation: Supports inference of potential interactions with biological pathways and receptors expressed in specific tissues.

Scientific Applications:

• Toxicological research: Predicts organ-specific effects of chemicals by linking HTS bioactivity to tissue expression profiles.
• Risk assessment and target identification: Identifies potential tissue targets of concern and informs mechanistic hypotheses for chemical toxicity pathways.

Methodology:

Maps assay targets from the Tox21 consortium onto human organs using organ-specific gene expression data and integrates bioactivity from 9,270 chemicals tested across 971 HTS assays to predict organ-specific effects.